The operating metrics private equity buyers use to evaluate outpatient physical therapy practices — what each metric measures, how buyers read it, and how each one moves enterprise value.
Every PT practice owner knows their revenue and their profit. Far fewer can recite the dozen operating metrics that a private equity buyer uses to decide why those numbers look the way they do — and whether they will hold up after closing. Buyers do not pay a multiple on EBITDA in the abstract. They pay a multiple on the unit economics that produce it: what each visit is worth, how many visits each clinic and clinician delivers, what each visit costs, and how stable the team and referral base are.
This paper sets out the twelve KPIs that dominate PT diligence in 2026, how buyers read each one — with reference points from the only remaining publicly traded pure-play outpatient PT operator — and a worked bridge showing how a single KPI improvement translates into enterprise value.
Two practices can report identical EBITDA — one through high productivity and strong contracts, the other through an owner treating 14 patients a day. Buyers use KPIs to separate durable earnings from fragile ones, and they price the difference.
A platform's post-close plan is built on levers: raise net rate per visit through its payer contracts, add visits through scheduling and marketing, and spread overhead. Your KPIs tell the buyer how much upside it can capture — and whether it can justify a higher bid.
KPIs that look "too good" — unusually high revenue per visit or visits per therapist — prompt coding and documentation audits. The best KPI profile is strong, explainable, and consistent with compliant billing.
Buyers request 24–36 months of monthly data. A KPI improving steadily for eight quarters is worth far more than a strong trailing twelve months with a recent downturn — buyers project the trend forward, not backward.
Reference points below are publicly reported results from U.S. Physical Therapy (USPH), alongside the diligence concerns described in Mihama's Quality of Earnings white paper. Platform results are directional for independent practices — your payer mix, market, and clinic size will move your numbers — but these are the metrics buyers will calculate from your data room.
| KPI | How to Calculate | Reference Point | How Buyers Read It |
|---|---|---|---|
| 1. Net revenue per visit (NRPV) | Net collected patient revenue ÷ billable visits | USPH $108.28 (Jan–Sep 2026) vs. $105.76 (FY 2025)3,9 | A high rate usually reflects heavier commercial and workers' comp mix; unusually high values prompt coding review |
| 2. Visits per clinic per day (VPCD) | Total visits ÷ clinic operating days | USPH 32.9 (Jan–Sep 2026) vs. 32.2 (FY 2025)3,9 | Capacity utilization: low VPCD means rent and staff are under-leveraged |
| 3. Visits per therapist per day | Visits ÷ treating-clinician days (FTE-adjusted) | Compared with peer platforms; values well above peers draw diligence scrutiny1 | Productivity vs. compliance: high values trigger 8-minute-rule and supervision review |
| 4. Same-clinic visit growth | Year-over-year visits at clinics open 12+ months | Compared with mature healthcare subsectors; sustained growth earns a premium1 | Separates organic demand from acquired or de novo growth |
| 5. Clinic-level EBITDA margin | Clinic EBITDA before corporate overhead ÷ clinic revenue | Compared with platform peers; top-quartile clinics earn a premium1 | The core unit economics a platform will inherit |
| 6. Corporate overhead | Shared G&A (billing, HR, marketing, leadership) ÷ total revenue | Falls as a share of revenue with scale; the leanest levels generally require substantial scale1 | Signals how much overhead a buyer can eliminate or spread |
| 7. Consolidated EBITDA margin | Adjusted EBITDA ÷ net revenue | Compared with platform peers; a margin well below peers signals problems1 | Headline quality, read in light of the owner's compensation normalization |
| 8. Labor cost per visit | Clinical salaries, benefits, and payroll taxes ÷ visits | USPH salaries & related costs: 58.6% of revenue (Jan–Sep 2026), consistent with $62.15 per visit on a $106.49 net rate in Q4 2025 (~58%)2,9,10 | Below-market pay is a retention risk; above-market pay compresses margin7 |
| 9. Clinician turnover | Clinician separations ÷ average clinician headcount | Industry turnover rose after COVID and remains elevated1 | High annual turnover is a hard QoE red flag7 |
| 10. Days in accounts receivable | AR balance ÷ average daily net revenue | Compared with revenue-cycle best practice; elevated days trigger pricing scrutiny7 | Revenue-cycle health; drives the working-capital peg |
| 11. Referral concentration | Top three referral sources' share of new patients | Heavy reliance on a few sources is material concentration risk7 | Durability of the patient pipeline after the owner exits |
| 12. Payer concentration | Largest single payer's share of revenue | Heavy reliance on one payer is a red flag7 | Exposure to one contract renegotiation or fee-schedule change |
USPH reported full-year 2025 net revenue of $781.0 million and adjusted EBITDA of $95.0 million — an adjusted EBITDA margin of about 12.2% — across roughly 780 clinics plus an industrial injury prevention segment.4,2 Through the first nine months of 2026 it reported adjusted EBITDA of $75.0 million on $634.9 million of revenue (about 11.8%) across 799 locations, and guided full-year 2026 adjusted EBITDA to $102–$106 million.9 Livingstone's tracker puts USPH's 2025 payer mix at roughly 49% commercial, 36% government, and 10% workers' compensation — richer in commercial and workers' comp than many independent practices, which helps explain its relatively high rate per visit.1 That ratio is not a like-for-like margin: USPH consolidates 100% of the revenue of its majority-owned partnership clinics, but its adjusted EBITDA excludes the share of earnings attributable to its clinic partners (noncontrolling interests), which understates clinic-level profitability.2 Use USPH for per-visit and per-clinic operating metrics, not for margin benchmarking.
Example A — Rate. A practice delivers 20,000 visits a year. A commercial renegotiation lifts its blended net revenue per visit by $5. Because rate improvements carry almost no incremental cost, nearly all of it reaches EBITDA.
Example B — Productivity. A practice has six full-time PTs averaging 10 visits per day over 240 working days. Better scheduling, reduced cancellations, and front-desk discipline raise that to 11 visits per day — a level that is still well supported by compliant documentation. Assume 90% of the added revenue reaches EBITDA (billing fees and supplies scale with volume).
Illustrative only. Assumes existing schedule capacity, payer mix unchanged, and fully compliant documentation. Because buyers value the practice on a multiple of EBITDA, each added dollar of EBITDA becomes several times that amount in enterprise value at closing.
Productivity well above peer norms draws diligence scrutiny.1 Buyers will reconcile billed timed units to scheduled minutes. A therapist billing more one-on-one units than the day physically allows is an "impossible day" — the first issue in Mihama's compliance white paper.8
Pair productivity data with documentation: group-therapy coding (97150) where appropriate, PTA and aide role definitions, and unit-to-minute reconciliations. Productivity backed by clean documentation is a premium; productivity without it is a liability.
BLS reports a May 2025 median annual wage of $102,760 for physical therapists and $68,380 for physical therapist assistants.5,6 At an identical 2,585 visits per year (11 per day × 235 days), that is about $39.75 vs. $26.45 in wages per visit — a $13.30 difference before benefits and payroll taxes.
Medicare pays services furnished in whole or in part by a PTA (CQ modifier) at 85% of the fee schedule. On a $100 Medicare visit, that is a $15 reduction — roughly equal to the wage savings, even after loading benefits at ~25% ($16.63). PTA leverage generally creates more margin on commercial and workers' comp visits than on Medicare visits.
Supervision Varies by State: CMS moved PTA supervision in private practice to general supervision effective January 1, 2025, but some state practice acts — including those of Arizona, Maryland, New Jersey, and Pennsylvania — still require direct, on-site supervision. Buyers check state law, not just Medicare rules — a staffing model that is compliant federally but not under your state act is a diligence finding.
By clinic, by provider, and by payer — including cancellations, no-shows, and new-patient evaluations.
Reconciled to the general ledger, with contract rate tables for each major payer.
Hire and separation dates, FTE status, compensation structure, and visits per day by clinician.
Rent, labor, and direct costs allocated by location so buyers can see clinic-level margins.
New patients by referring provider and channel, including direct-access and self-referral.
0–30 through 120+ day buckets, denial rates, and write-off history.
Timed-unit-to-minute samples, KX modifier usage, RTM logs, and PTA supervision documentation.
Trailing eight quarters for all twelve KPIs. If you cannot produce it in a day, a buyer will assume the business is not managed by the numbers.
Mihama builds a confidential KPI scorecard for your practice against current buyer benchmarks, identifies the two or three metrics that move your value most, and helps you fix them before diligence begins.
347-878-2941
Confidential consultation, no retainer required
info@mihamainc.com
We respond within one business day
www.mihamainc.com
Resources, white papers & transaction experience
Industry-index figures reflect the methodology and cohort of the Livingstone Partners Physical Therapy Tracker. USPH figures are company-reported, non-GAAP where noted, and reflect a partnership structure that differs from a typical independent practice; 2026 USPH figures are for the nine months ended September 30, 2026, and USPH began reporting salaries and related costs as a percentage of revenue in 2026. Bridge examples are illustrative.